NASDAQ:LIMN Liminatus Pharma Q1 2026 Earnings Report $3.83 +0.13 (+3.54%) As of 02:34 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Liminatus Pharma EPS ResultsActual EPS-$1.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALiminatus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALiminatus Pharma Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Liminatus Pharma Earnings HeadlinesLiminatus Pharma Inc. (NASDAQ:LIMN) Shares Shorted: Short Interest Down 38.4% in SeptemberOctober 3, 2026 | americanbankingnews.comLiminatus Pharma Regains Nasdaq Compliance Following 1-For-50 Reverse SplitSeptember 30, 2026 | rttnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)Liminatus Pharma regains NASDAQ complianceSeptember 29, 2026 | msn.comLiminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price RuleSeptember 29, 2026 | globenewswire.comLiminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyAugust 24, 2026 | globenewswire.comSee More Liminatus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email. Email Address About Liminatus PharmaLiminatus Pharma (NASDAQ:LIMN), Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases with significant unmet medical needs. The company’s primary activities involve advancing pharmaceutical candidates through research and development, including preclinical and clinical testing. Publicly available information indicates that its work is centered on potential treatments in areas such as oncology and related therapeutic applications, rather than on marketed commercial products. Liminatus Pharma is listed on the Nasdaq under the symbol LIMN. Detailed information about its specific product pipeline, geographic operations and leadership is limited in publicly available sources.View Liminatus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Penguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry Point Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
